INDEMNIFICATION AGREEMENTIndemnification Agreement • March 10th, 2023 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • Delaware
This Indemnification Agreement (“Agreement”) is made as of _________, 2023 by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and ________ (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 10th, 2023 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • Massachusetts
This Employment Agreement (hereinafter the “Agreement”) is made as of January 3, 2023 (the “Effective Date”), by and between Michael Pine, who currently resides at xxx (“Employee”) and EyePoint Pharmaceuticals, Inc. (hereinafter together with its subsidiaries, and related or affiliated entities referred to as the “Company”), having its headquarters at 480 Pleasant Street, Suite C-400, Watertown, Massachusetts 02472 (collectively the “Parties”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Commercial Alliance Agreement • March 10th, 2023 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments
EyePoint Pharmaceuticals, Inc. (“EyePoint”) and ImprimisRx, LLC (“Imprimis”) entered into a Commercial Alliance Agreement effective as of August 1, 2020, as modified by the Letter
THIRD Amendment to Loan and security agreementLoan and Security Agreement • March 10th, 2023 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
This Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 7th day of March, 2023, by and among (a) SILICON VALLEY BANK (“Bank”) and (b) (i) EYEPOINT PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), (ii) EYEPOINT PHARMACEUTICALS US, INC., a Delaware corporation (“EyePoint US”), and (iii) ICON BIOSCIENCE, INC., a Delaware corporation (“Icon”, together with Parent and EyePoint US, individually and collectively, jointly and severally, the “Borrower”) whose address is 480 Pleasant Street, Suite A210, Watertown, Massachusetts 02472.
LEASELease • March 10th, 2023 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments
This Lease made this 23rd day of January, 2023, by and between V.E. Properties IX, LLC, a Delaware limited liability company, having its usual place of business at One Memorial Square, P.O. Box 67, Whitinsville, Massachusetts 01588 (hereinafter, with its successors and assigns, the “Lessor”) and EyePoint Pharmaceuticals US, Inc., a Delaware corporation, having its usual place of business at 480 Pleasant Street, Suite A210, Watertown, Massachusetts 02472 (hereinafter, with its successors and assigns, the “Lessee”).
SECOND Amendment to Loan and security agreementLoan and Security Agreement • March 10th, 2023 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments
This Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 6th day of December, 2022, by and among (a) SILICON VALLEY BANK (“Bank”) and (b) (i) EYEPOINT PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), (ii) EYEPOINT PHARMACEUTICALS US, INC., a Delaware corporation (“EyePoint US”), and (iii) ICON BIOSCIENCE, INC., a Delaware corporation (“Icon”, together with Parent and EyePoint US, individually and collectively, jointly and severally, the “Borrower”) whose address is 480 Pleasant Street, Suite A210, Watertown, Massachusetts 02472.
